Under the exclusive agreement, Fisher Healthcare, which is part of Thermo Fisher Scientific, will distribute the test through its channel.
The IVD industry is optimistic that political tensions between the US and China won't slow down their businesses. However, other challenges may lay ahead for them.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
Under the agreement, Biodesix will use the Thermo Fisher Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to generate data to apply for FDA premarket approval.
Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.